Skip to content
Tablet Allopathic

Vildagil 50 mg tablet

Generic: Vildagliptin

Company: Not listed yet. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength50 mg
PackBox of 20: 360.80 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated September 7, 2024.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Vildagliptin 50 mg tablets

Prices as listed on BestinMeds.

2 brands listed
Vildaglip, box of 2012.00 taka per tablet
Vildagil, box of 20 (this medicine)18.04 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Vildagliptin guide

Indications

Type 2 DM Vildagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus as monotherapy and in dual combination with Metformin, a Sulphonylurea, a Thiazolidinedione, or Insulin when diet, exercise and a single antidiabetic agent do not result in adequate glycemic control.

Dosage and administration

The recommended dose of Vildagliptin is- 50 mg or 100 mg daily for monotherapy. 50 mg twice daily (morning and evening) when used in dual combination with Metformin or a Thiazolidinedione; 50 mg once daily in the morning when used in dual combination with a Sulphonylurea. Vildagliptin may be taken with or without a meal. No dosage adjustment is required in the elderly, or in patients with mild renal impairment.Pediatric use: Vildagliptin is not recommended in patients 18 years of age.

Side effects

The majority of adverse reactions were mild and transient, not requiring treatment discontinuations. A rare case of hepatic dysfunction is seen. Clinical trials of up to and more than 2 years duration did not show any additional safety signals or unforeseen risks when using this combination.

Precautions and warnings

Caution should be exercised in patients aged 75 years and older due to limited clinical experience. It is recommended that LFTs are monitored prior to initiation of Vildagliptin, at three-monthly intervals in the first year and periodically thereafter. If transaminase levels are increased, patients should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality returns to normal. If AST or ALT persists at 3xULN, Vildagliptin treatment should be stopped. Patients who develop jaundice or other signs of liver dysfunction should discontinue Vildagliptin. Following the withdrawal of treatment with Vildagliptin and LFT normalization, treatment with Vildagliptin should not be reinitiated. Due to limited clinical experience, use with caution in patients with congestive heart failure of New York Heart Association (NYHA) functional class I-II, and do not use in patients with NYHA functional class III IV.

Pregnancy and lactation

Vildagliptin should not be used in pregnancy. Vildagliptin should not be used during lactation.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250